Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Darpö, B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Darpö, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes

B. Darpö*

Department of Cardiology, Karolinska Hospital, Stockholm, and Quintiles Services, Stockholm, Sweden

* Correspondence: Börje Darpö, MD, Associate Professor, Quintiles Services, Hornsbergsg. 17, SE-11251, Stockholm, Sweden.

Abstract

The incidence of drug-induced proarrhythmias in the general population is largely unknown. Knowledge regarding incidence and risk factors is mainly derived from studies during clinical development of drugs and is therefore limited to antiarrhythmic compounds with a relatively high incidence. For non-cardiovascular drugs, proarrhythmias are rarely seen during clinical development but usually appear later, several years after registration. Both spontaneous adverse reaction reports and epidemiological studies have severe limitations when used to estimate the incidence of proarrhythmias with non-cardiovascular compounds. QT prolongation and torsades de pointes have been associated with non-sedating antihistamines, antibiotics, antipsychotics, antidepressants and a gastrointestinal prokinetic agent; drugs within these classes constitute the vast majority of non-cardiovascular compounds associated with this potentially serious side-effect. Epidemiological studies on non-sedating antihistamines and on cisapride have largely failed to demonstrate an increased risk for sudden death or ventricular arrhythmias, which is most likely due to the low specificity of the end-points studied. A careful case ascertainment, which requires access to electrocardiograms and clinical records, and prospectively defined, strict definitions for the classification of proarrhythmias, is of great importance in these studies.

Key Words: Torsades de pointes • QT prolongation • noncardiovascular drugs • epidemiology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
W. A. Ray, C. P. Chung, K. T. Murray, K. Hall, and C. M. Stein
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
N. Engl. J. Med., January 15, 2009; 360(3): 225 - 235.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.